The Regenexx® family of non-surgical stem cell and blood platelet procedures offer next-generation injection treatments for those who are suffering from knee pain or may be facing knee surgery or knee replacement due to common tendon, ligament and bone injuries, arthritis and other degenerative conditions.
As an alternative to knee surgery or knee replacement, Regenexx procedures may help alleviate knee pain and the conditions that cause it with a same-day office injection procedure. Unlike traditional surgery, Regenexx patients are typically encouraged to walk the same day, and most patients experience very little down time from the procedure.
Commonly Treated Knee Conditions - Regenexx Stem Cell and Platelet Procedures
Commonly Treated Knee Conditions
This is not a complete list of conditions treated, but the most common knee conditions we have treated throughout the years. If you are experiencing knee pain, injury, or arthritis, please contact us or complete the candidacy form below to learn more about whether the Regenexx Procedures are right for you.
- Patellofemoral Syndrome/Chondomalacia
- Pes anersine bursitis
- Baker’s cyst
- Patellar tendonitis
- Meniscus tear
- MCL sprain or tear
- ACL sprain or tear
- PCL sprain or tear
- LCL sprain or tear
- Biceps Femoris Insertional Tendinopathy
- Hamstrings Tendinopathy
Dr. John Pitts Discusses Common Knee Injuries and TreatmentsInfographics showing the causes of patellofemoral pain and treatments using the Orthopedics 2.0 approach Infographic on the common causes of chronic knee pain and why what’s seen on your MRI might not be the whole story…
Regenexx Knee Patient Outcome Data
Knee Patient Outcome Data
This Regenexx bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry.View Knee Patient Outcome Data Here
Knee Meniscus Procedure Outcome Data
This Regenexx bone marrow derived stem cell treatment outcome data analysis is part of the Regenexx data download of patients who were tracked in the Regenexx advanced patient registry following treatment for Meniscus Tears.View Knee Meniscus Procedure Outcome Data Here
Knee Function Improvement Data
This data utilizes LEFS (Lower Extremity Functional Scale) data from our knee arthritis patients treated with stem cell injections. Functional questionnaires ask the patients questions such as how well they can walk, run, climb stairs, etc. The improvements following the Regenexx Stem Cell Procedure are highly statistically significant.View Knee Function Improvement Data Here
Interested in Joint Replacement vs Stem Cell Procedure Data?
If you are considering a knee replacement, watch the video in the sidebar of this page and read about how stem cells stack up against knee replacements.
Recently Published Research on Regenexx Stem Cell Procedure for Knee Osteoarthritis
Introduction. We investigated the use of autologous bone marrow concentrate (BMC) with and without an adipose graft, for treatment of knee osteoarthritis (OA). Methods. Treatment registry data for patients who underwent BMC procedures with and without an adipose graft were analyzed. Pre- and posttreatment outcomes of interest included the lower extremity functional scale (LEFS), the numerical pain scale (NPS), and a subjective percentage improvement rating. Multivariate analyses were performed to examine the effects of treatment type adjusting for potential confounding factors. The frequency and type of adverse events (AE) were also examined. Results. 840 procedures were performed, 616 without and 224 with adipose graft. The mean LEFS score increased by 7.9 and 9.8 in the two groups (out of 80), respectively, and the mean NPS score decreased from 4 to 2.6 and from 4.3 to 3 in the two groups, respectively. AE rates were 6% and 8.9% in the two groups, respectively. Although pre- and posttreatment improvements were statistically significant, the differences between the groups were not. Conclusion. BMC injections for knee OA showed encouraging outcomes and a low rate of AEs. Addition of an adipose graft to the BMC did not provide a detectible benefit over BMC alone.